Ann: Chimeric receives $2.5 M advance on FY25 R&D tax incentive, page-23

First 23 Last

Share
Profile

Follow
ThePig

3,169 Posts.

1782

12/06/25

11:45

Post #: 79404895
Share

Originally posted by dalts66: ↑

For someone who expects compliance with all i dotted and all Ts. crissed from a BOD, you surprise me how you accept mediocre research from yourself.

You were wrong when you stated your option fix when the CR was done. You were wrong when stating the amount they have in the bank now. Yet you still think your ideas are better than those running the company.

As has been explained to you many times, option money can not be relied upon until after the option expiry. Regardless of how far they are in the money. And that expiry date would be after the date the tax refund could be available. We need arms being dosed now. Without money, we can't do that. Without having arms dosed, the company can't build the share price. So your idea would mean that graph would continue as it is.
CHM is fast approaching a point where a partner comes on board. I find that an exciting opportunity. This could potentially happen before the calendar year end if we get the right data.
Dr Bec ensuring we are funded to achieve this seems like the right thing to me. As CHM is funded to plan and dose arms. Your idea would leave them waiting to see how much money they get as the option expiry date approaches. Greatly delaying the trial progress.

This doesn't seem like a very hard concept to understand. This is the very high risk end of the market. CHM has two major risks. One is finance, the other is the drug performance. Dr Bec and team have just done their best to mitigate the financial problem to some point after where the opportunity for a partner exists. I like that. The drug so far has shown promise.
So, the risk has finally swapped from being the dollars in the bank to drug performance. That's the best situation CHM has been in for many years.

Expand

$11.6m that I stated came from this:

Please provide evidence of my inaccurate 'option fix when the CR was done'.

CHM Price at posting: 0.4¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

LRV

Larvotto hits "go" on Hillgrove Project

SS1

Sun Silver unveils Maverick Springs assay results

HotCopper Trends: Final day of quarterlies; Larvotto FID & more

Investor education equals superior returns

I88

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

First 23 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.3¢		Change -0.001(25.0%)		Mkt cap ! $9.747M

Open	High	Low	Value	Volume
0.3¢	0.4¢	0.3¢	$11.33K	3.775M

Buyers (Bids)

No.	Vol.	Price($)
75	71644408	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	87927011	26

View Market Depth

No.	Vol.	Price($)
75	71644408	0.003
30	29940488	0.002
13	53914001	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	87927011	26
0.005	34943562	24
0.006	17929018	21
0.007	6512518	7
0.008	7317101	5

Last trade - 14.48pm 31/07/2025 (20 minute delay)

CHM (ASX) Chart

Ann: Chimeric receives $2.5 M advance on FY25 R&D tax incentive, page-23

Larvotto hits "go" on Hillgrove Project

Sun Silver unveils Maverick Springs assay results

HotCopper Trends: Final day of quarterlies; Larvotto FID & more

Investor education equals superior returns

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Chimeric receives $2.5 M advance on FY25 R&D tax incentive, page-23

Top Stories

Larvotto hits "go" on Hillgrove Project

Sun Silver unveils Maverick Springs assay results

HotCopper Trends: Final day of quarterlies; Larvotto FID & more

Investor education equals superior returns

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News